Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Source :: PR Newswire. October 30, 2024
Publication Year :: 2024
Abstract: Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for [...]

Subjects :: Boehringer Ingelheim GmbH -- Company sales and earnings
Eli Lilly and Co. -- Company sales and earnings
Olanzapine
Pharmaceutical industry -- Company sales and earnings
Insulin lispro
Company earnings/profit
Business
News, opinion and commentary
Trulicity (Medication)
Ebglyss (Medication)
Verzenio (Medication)
Mounjaro (Medication)
Zepbound (Medication)

Tools